No serious adverse events related to hemolysis have occurred in G6PD normal individuals with >70% activity; however, in a malaria prophylaxis, clinical efficacy trial two females with G6PD deficiency were misclassified as G6PD normal. This evidence concerns the gene G6PD and malaria.